The Patient: Patient-Centered Outcomes Research

, Volume 4, Issue 3, pp 177–187 | Cite as

Establishing the Content Validity of the King’s Health Questionnaire in Men and Women with Overactive Bladder in the US

  • Mary Kay Margolis
  • Vasudha Vats
  • Karin S. Coyne
  • Con Kelleher
Original Research Article

Abstract

Background: Overactive bladder (OAB) consists of the symptoms of urinary urgency (with or without urgency incontinence) and increased urinary frequency and nocturia. As OAB is defined by symptoms, the patient is the best source of information for assessing the impact of the condition on health-related quality of life (HR-QOL). This assessment can be conducted through the use of valid patient-reported questionnaires, meaning the questionnaire has demonstrated content validity, among other acceptable psychometric properties. The aim of this study was to evaluate the content validity of the King’s Health Questionnaire (KHQ) in patients with OAB in the US.

Methods: Men and women with continent or incontinent OAB were recruited from a clinical research site in the US. Participants completed the KHQ and were then asked about the instructions, items, and response options. Data were analyzed descriptively and qualitatively.

Results: A total of 24 participants (18 women, 6 men; mean [±SD] age 59.0±11.1 years) with OAB were interviewed and provided feedback on the KHQ. Participants reported that overall, the KHQ covers the key aspects in which OAB impacts patients’ daily lives. Most KHQ items and response options were acceptable and understandable to the participants; however, a few minor issues were noted. In item 3, shopping was not considered by some participants to be a household task, while shopping and cleaning were not relevant to some of the men. Two sets of items (‘limit social life’ and ‘limit ability to see/visit friends’ and ‘bladder problem affect sleep’ and ‘feel worn out or tired’) were perceived as redundant, while ‘depressed’ (item 12) and ‘anxious or nervous’ (item 13) were perceived by some participants as too intense. Some participants were unsure if the intended meaning of ‘change your underclothes when they get wet’ was about changing wet underwear or frequency of incontinence episodes.

Conclusion: The KHQ demonstrated content validity and can be considered a relevant and appropriate tool to assess the impact of OAB on HR-QOL in men and women in the US.

Keywords

Urinary Incontinence Content Validity Personal Relationship Overactive Bladder Urgency Incontinence 

Notes

Acknowledgements

Funding for this study and approval for the manuscript was provided by Pfizer Inc. Mary Kay Margolis and Karin Coyne are employees of United BioSource Corporation, who were paid scientific consultants to Pfizer Inc. Vasudha Vats is an employee of Pfizer Inc. Con Kelleher is a scientific consultant for Pfizer Inc.

Mary Kay Margolis participated in the design and coordination of the study, performed the analyses, and drafted the manuscript. Vasudha Vats conceived the study and assisted in drafting the manuscript. Karin Coyne participated in the design of the study, performed the analyses, and drafted the manuscript. Con Kelleher developed the KHQ and reviewed the analyses and draft manuscript. All authors read and approved the final manuscript.

References

  1. 1.
    Irwin DE, Milsom I, Hunskaar S, et al. Population-based surve of urinar incontinence, overactive bladder, and other lower urinar tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 Dec; 50(6): 1306–15PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20(6): 327–36PubMedGoogle Scholar
  3. 3.
    Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminolog report: the ongoing debate. Neurourol Urodyn 2009; 28(4): 287PubMedCrossRefGoogle Scholar
  4. 4.
    Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinar incontinence and overactive bladder on qualit of life. Eur Urol 2003 May; 43(5): 535–8PubMedCrossRefGoogle Scholar
  5. 5.
    Liberman JN, Hunt TL, Stewart WF, et al. Health-related qualit of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 2001 Jun; 57(6): 1044–50PubMedCrossRefGoogle Scholar
  6. 6.
    Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related qualit of life questionnaire: the OAB-q. Qual Life Res 2002 Sep; 11(6): 563–74PubMedCrossRefGoogle Scholar
  7. 7.
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validit of qualit of life claims for labeling and promotion. Value Health 1999 Mar–Apr; 2(2): 113–27PubMedCrossRefGoogle Scholar
  8. 8.
    Wynd CA, Schmidt B, Schaefer MA. Two quantitative a roaches for estimating content validity. West J Nurs Res 2003 Aug; 25(5): 508–18PubMedCrossRefGoogle Scholar
  9. 9.
    Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the qualit of life of urinar incontinent women. Br J Obstet Gynaecol 1997 Dec; 104(12): 1374–9PubMedCrossRefGoogle Scholar
  10. 10.
    Kobelt G, Kirchberger I, Malone-Lee J. Review: quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999 Apr; 83(6): 583–90PubMedCrossRefGoogle Scholar
  11. 11.
    Kochakarn W, Pummangura N, Kijvikai K, et al. Reliabilit of a Thai version of King’s Health Questionnaire in Thai females with overactive bladder symptoms. J Med Assoc Thai 2005 Nov; 88(11): 1526–34PubMedGoogle Scholar
  12. 12.
    Okamura K, Usami T, Nagahama K, et al. The relationships among filling, voiding subscores from International Prostate Symptom Score and qualit of life in Japanese elderl men and women. Eur Urol 2002 Nov; 42(5): 498–505PubMedCrossRefGoogle Scholar
  13. 13.
    Reese PR, Pleil AM, Okano GJ, et al. Multinational stud of reliabilit and validit of the King’s Health Questionnaire in patients with overactive bladder. Qual Life Res 2003 Jun; 12(4): 427–42PubMedCrossRefGoogle Scholar
  14. 14.
    Tamanini JT, Dambros M, D’Ancona CA, et al. Concurrent validity, internal consistenc and responsiveness of the Portuguese version of the King’s Health Questionnaire (KHQ) in women after stress urinar incontinence surgery. Int Braz J Urol 2004 Nov–Dec; 30(6): 479–86PubMedCrossRefGoogle Scholar
  15. 15.
    Uemura S, Homma Y. Reliabilit and validit of King’s Health Questionnaire in patients with symptoms of over-active bladder with urge incontinence in Japan. Neurourol Urodyn 2004; 23(2): 94–100PubMedCrossRefGoogle Scholar
  16. 16.
    US Food and Drug Administration. Guidance for industry: patient-reported outcome measures. Use in medical product development to su ort labeling claims [online]. Available from URL: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM193282. pdf [Accessed 2010 Jan 1]Google Scholar
  17. 17.
    Homma Y, Kawabe K. Health-related qualit of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxy-butynin: a randomized, placebo-controlled trial. World J Urol 2004 Oct; 22(4): 251–6PubMedCrossRefGoogle Scholar
  18. 18.
    Junemann KP, Hessdorfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficac and tolerabilit in patients with overactive bladder. Urol Int 2006; 77(4): 334–9PubMedCrossRefGoogle Scholar
  19. 19.
    Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related qualit of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 Dec; 8(19 Su l.): S616–30PubMedGoogle Scholar
  20. 20.
    Kelleher CJ, Reese PR, Pleil AM, et al. Health-related qualit of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002 Dec; 8(19 Su l.): S608–15PubMedGoogle Scholar
  21. 21.
    Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. BJU Int2007 Jan; 99(1): 101–6PubMedCrossRefGoogle Scholar
  22. 22.
    Pleil AM, Reese PR, Kelleher CJ, et al. Health-related qualit of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC 2001; 2: 69–75CrossRefGoogle Scholar
  23. 23.
    Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminar report from the Multicenter Assessment of Transdermal Therap in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006 Dec; 195(6): 1730–5PubMedCrossRefGoogle Scholar
  24. 24.
    Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinar urgency: a randomized placebo-controlled trial. Urology 2006 Nov; 68(5): 999–1004PubMedCrossRefGoogle Scholar
  25. 25.
    Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 2004 Jan; 63(1): 61–6PubMedCrossRefGoogle Scholar
  26. 26.
    Coyne K, Margolis MK, Weinstein D, et al. Health-related qualit of life differences between men and women with OAB treated with fesoterodine. IUGA 33rd Annual Meeting; 2008 Sep 15–17; TaipeiGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Mary Kay Margolis
    • 1
  • Vasudha Vats
    • 2
  • Karin S. Coyne
    • 1
  • Con Kelleher
    • 3
  1. 1.United BioSource CorporationCenter for Health Outcomes ResearchBethesdaUSA
  2. 2.Pfizer, IncNew YorkUSA
  3. 3.Guys and St. Thomas’ NHS Foundation TrustSt. Thomas’ HospitalLondonUK

Personalised recommendations